PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, at 2:00 p.m. ET. The live and archived fireside chat will be accessible from the Company’s website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will b ...

Financial Performance - Q3 2025 revenue reached $143 million, reflecting an 8% increase compared to Q3 2024[7] - Adjusted Gross Margin was 38.9% in Q3 2025, a 66 bps increase from Q3 2024[7, 38] - Adjusted Diluted EPS was $0.60 in Q3 2025, a (2)% decrease compared to Q3 2024[7] Segment Performance - Diversified end markets (industrial, aerospace & defense, and medical) saw a 22% revenue increase year-over-year and accounted for 59% of total revenue[10, 38] - Transportation end market revenue decreased by (7)% year-over-year due to lower commercial vehicle sales[10, 38] - Total booked business in transportation was approximately $1 billion at the end of Q3 2025[25] End Market Highlights - Medical Q3 sales were $22 million, up 22% year-over-year, with bookings up 8%[17] - Aerospace & Defense Q3 sales were $25 million, up 23% year-over-year, with bookings up 29%[17] - Industrial Q3 sales were $37 million, up 21% year-over-year, with bookings up 29%[25] Cash Flow and Balance Sheet - Generated $29 million in operating cash flow in Q3 2025[10] - Free cash flow YTD 2025 was $60 million[40] - Cash returned to shareholders YTD 2025 totaled $44 million[40]

Core Insights - California is experiencing a pharmaceutical renaissance, driven by significant investments from major biopharma companies like Amgen and Gilead, focusing on science, supply chains, and innovative therapies [1][4]. Group 1: Amgen's Investment - Amgen has invested $600 million to establish a state-of-the-art science and innovation center at its headquarters in Thousand Oaks, CA, aimed at enhancing collaboration among scientists, engineers, and researchers [2]. - This investment is part of Amgen's broader strategy, which has seen the company allocate over $40 billion into domestic manufacturing and R&D since the 2017 Tax Cuts and Jobs Act, including more than $5 billion in direct capital expenditures [3]. Group 2: Gilead's Development Initiatives - Gilead Sciences has initiated the construction of a new Technical Development Hub to accelerate biopharma innovation in the U.S., highlighting the importance of specialized infrastructure in the industry [4]. Group 3: Supply Chain Modernization - The investments from these companies also contribute to the modernization of supply chains, which are now viewed as critical systems requiring transparency, flexibility, and resilience [5]. - Advanced cold chain management practices are being developed, utilizing predictive analytics to monitor not only temperature but also equipment functionality, which is essential for therapeutic delivery [6]. Group 4: California's Biopharma Ecosystem - The current investments reflect California's reassertion as a national life sciences engine, fostering partnerships between academia and startups through its R&D hubs [8].

Company Overview - ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company focused on developing, manufacturing, and commercializing innovative therapeutics [3] - The company aims to deliver sustainable growth through its Rare Disease business, Generics business, and Brands business [3] Upcoming Event - ANI Pharmaceuticals will present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 1:30 PM ET [1] - A live and archived webcast of the presentation will be available on the company's website for 90 days [2]